Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
257 results about "Betulinic acid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Betulinic acid is a naturally occurring pentacyclic triterpenoid which has antiretroviral, antimalarial, and anti-inflammatory properties, as well as a more recently discovered potential as an anticancer agent, by inhibition of topoisomerase. It is found in the bark of several species of plants, principally the white birch (Betula pubescens) from which it gets its name, but also the ber tree (Ziziphus mauritiana), selfheal (Prunella vulgaris), the tropical carnivorous plants Triphyophyllum peltatum and Ancistrocladus heyneanus, Diospyros leucomelas, a member of the persimmon family, Tetracera boiviniana, the jambul (Syzygium formosanum), flowering quince (Pseudocydonia sinensis, former Chaenomeles sinensis KOEHNE), rosemary, and Pulsatilla chinensis.
Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
Salts of 3-O-(3′,3′-dimethylsuccinyl)Betulinic acid (DSB) are disclosed. Particularly, the preparation, pharmaceutical evaluation, and in vivo bioavailability evaluation of N-methyl-D-glucamine and alkali metal salt forms of DSB are disclosed. Pharmaceutical compositions including these salt forms are used in methods of treating HIV and related diseases. Methods of making the salts of DSB and the pharmaceutical compositions are also provided.
Owner:MYREXIS INC
Compositions for Regulation of Hair Growth
InactiveUS20080254055A1Reduce frequencyImprove shaving efficiencyBiocideCosmetic preparationsPersonal carePhytic acid
Personal care composition comprising at least one hair growth regulating compound selected from the group consisting of glyceryl dilaurate, apigenin, tetrahydrocurcumin, oleanolic acid, azelaic acid, sulforaphane, canavanine, pyridoxal 5-phosphate, phytic acid, tannic acid, grape seed extract, NG-nitro-L-arginine-methyl ester, benzamidine, sodium butyrate, betulinic acid, polyornithine, polyarginine, fisetin, jasmonates, methyl-jasmonate, cis-jasmone, caffeic acid phenethyl ester, delphinidin, ethyl abietate, esculetin, sorbic acid methyl ester, canaline, N-formyl-methionine, N-formyl-alanine, taurine, palmitoyl carnitine, undecanol, undecylenic acid, rutin, fusidic acid, phenyl pyruvic acid, L-isoleucine, phenyl glycine, silibinin, silymarin, L-ascorbic acid-6-palmitate, N-undecylenoyl-L-phenylalanine, and salts, derivatives and mixtures of any of the foregoing; and a dermatologically-acceptable carrier.
Owner:THE PROCTER & GAMBLE COMPANY
Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor
The present invention is, generally, directed to the use of betulinic acid and derivatives thereof for the treatment of neuroectodermal tumors. The present invention is based on the discovery that betulinic acid and its derivatives are potent anti-neuroectodermal agents. As disclosed herein, betulinic acid and its derivatives are useful for the treatment of neuroectodermal tumors, including, due to its distinct mechanism of action, neuroectodermal tumors that are resistant to conventional chemotherapeutical agents. In addition to the new use of known compounds, the invention discloses novel compounds and pharmaceutical compositions for the treatment of neuroectodermal tumors.
Owner:DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS
Betulinic Acid Derivatives and Methods of Use Thereof
InactiveUS20120101149A1Improve clearanceIncrease ratingsBiocideNervous disorderStereochemistryBetulinic acid
This invention features betulinic acid derivatives having the formula: wherein the variables are defined herein. The invention also provides related compounds and intermediates thereof, as well as pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Treatment methods and methods of manufacture are also provided.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE +1
Betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis
InactiveUS6403816B1Synthesis cost is highLow costSteroidsAmine active ingredientsAngiogenesis growth factorStereochemistry
The invention relates to novel betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis.
Owner:DABUR PHARM LTD
Modified c-3 betulinic acid derivatives as HIV maturation inhibitors
InactiveUS20120142707A1Effective antiviral agentUseful in treatmentBiocidePeptide/protein ingredientsNatural productMaturation inhibitor
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
Owner:VIIV HEALTHCARE UK (NO 5) LTD
C-28 amides of modified c-3 betulinic acid derivatives as HIV maturation inhibitors
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
Owner:VIIV HEALTHCARE UK (NO 5) LTD
23-Hydroxyl betulinic acid kind derivant and preparing process, preparation and use thereof
A kind of modified 23-hydroxy betulic acid derivatives, their preparing process, the medicinal composition containing them and their application in preventing and treating tumor are disclosed.
Owner:CHINA PHARM UNIV
C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Triterpenoids and Compositions Containing the Same
The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Triterpenoids and compositions containing the same
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
C-28 amines of c-3 modified betulinic acid derivatives as HIV maturation inhibitors
InactiveUS20130029954A1Useful in treatmentBiocideOrganic active ingredientsPharmaceutical drugPharmaceutical medicine
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS. In particular, the following compounds are provided herein, including pharmaceutically acceptable salts thereof:a compound of formula Ia compound of formula IIand a compound of formula III
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Modified C-3 betulinic acid derivatives as HIV maturation inhibitors
Owner:VIIV HEALTHCARE UK (NO 5) LTD
C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Use of betulinic acid in preparing glycosidase inhibitor medicine
InactiveCN101416971ALow costRich sourcesOrganic active ingredientsMetabolism disorderLupeolDrug excipient
The invention provides the application of betulinic acid and salts thereof suitable for medical purpose in the preparation of a drug of a glycosidase inhibitor. The compound of the invention is the compound of lupeol type pentacyclic triterpene acid obtained by separating lagerstroemia plants. Pharmacological tests prove that the compound has obvious effect in inhibiting Alpha-glucosidase, the inhibitory activity of which exceeds acarbose 100% for initial therapy. Therefore, drug compositions made from the compound or the salts thereof suitable for medical purpose and drug excipients or carriers allowable for preparation can be applied to the preparation of drugs for preventing or treating Type II Diabetes, namely, noninsulin-dependent diabetes mellitus. The constitutional formula shown in formula (1) of the invention is shown as above.
Owner:ZHEJIANG UNIV
Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
A method for the treatment of obesity, diabetes, high cholesterol and related diseases including hyperglycemia, lipid disorders, hyperglyceridemia, dyslipidemia and atherosclerosis in mammals using anthocyanins, anthocyanidins, ursolic acid and / or betulinic acid is described. Compositions adapted for these treatments are also described.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV
Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
ActiveUS20130303797A1Organic compound preparationCarboxylic acid esters preparationSumaresinolic acidUrsolic acid
The present invention is a method for preparing triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester and derivatives thereof from oleanic acid, ursolic acid, betulinic acid, sumaresinolic acid or hederagenin.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
23-hydroxy betulinic acid derivative as well as preparation method and application thereof
ActiveCN102108092APrevent proliferationInhibitory activityOrganic active ingredientsSteroidsNon toxicityAcid derivative
The invention discloses a 23-hydroxy betulinic acid derivative as well as a preparation method and application thereof. The derivative has a structure as shown in a formula (I). The 23-hydroxy betulinic acid derivative can be used for resisting tumors and used as a tumor medicament resistance reversal agent. The 23-hydroxy betulinic acid derivative can be used for effectively inhibiting the proliferation of tumor cells and also can be used for obviously increasing the antipersonnel force of DOX (doxorubicin) on a P-glycoprotein overexpression cell strain HepG2 / ADM under the condition of non-toxicity dosage.
Owner:JINAN UNIVERSITY
Method of preparing and use of prodrugs of betulinic acid derivatives
InactiveUS20070072835A1Prevent and inhibit tumor growthPreventing and inhibiting growthBiocideOrganic active ingredientsAbnormal tissue growthCompound (substance)
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Triterpenoids and compositions containing the same
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Betulinic acid, derivatives and analogs thereof and uses therefor
Provided herein provided herein are novel analogs and derivatives of betulinic acid. Also provided is a method for inhibiting an activity of one or more specificity protein (Sp) transcription factors cells associated with a neoplastic disease using betulinic acid, betulinic acid analog(s) and / or derivative(s) effective to decrease expression of a microRNA with concomitant increase in Sp suppressor gene expression. The betulinic acid analogs and derivatives also are effective in methods provided herein for inhibiting proliferation of cells associated with a neoplastic disease for treating a cancer or for reducing toxicity of a cancer therapy in a subject via administration of an analog or derivative of betulinic acid and, optionally, another anticancer drug.
Owner:SAFE STEPHEN H +1
Birch bark processing and the isolation of natural products from birch bark
InactiveUS6815553B2Not costly and lengthy and dangerous procedureEasy to handleSolvent extractionOrganic compound preparationNatural productBetula platyphylla
The invention provides methods for separating outer birch bark from inner birch bark. The invention also provides methods for isolating betulin; lupeol; betulinic acid; 9,10-epoxy-18-hydroxyoctadecanoic acid; 9,10,18-trihydroxyoctadecanoic acid; polyphenolic polymers and fatty acids from birch bark.
Owner:RGT UNIV OF MINNESOTA
Birch bark processing and the isolation of natural products from birch bark
InactiveUS20050158414A1Not costly and lengthy and dangerous procedureEasy to handleBiocideSolvent extractionNatural productBetula platyphylla
Owner:RGT UNIV OF MINNESOTA
Selective oxidation of triterpenes employing tempo
The present invention provides a process of preparing betulin-28-aldehyde from betulin. The process includes contacting betulin with a compound of formula (I), e.g., TEMPO (2,2,6,6-tetramethylpiperidine 1-oxyl) for a period of time effective to provide betulin-28-aldehyde. The present invention also provides a process of preparing betulinic acid. The process includes contacting betulin with a composition that includes: sodium hypochlorite (NaOCl); sodium chlorite (NaClO2), potassium chlorite (KClO2), or a combination thereof; and a compound of formula (I), e.g., TEMPO (2,2,6,6-tetramethylpiperidine 1-oxyl); for a period of time effective to provide betulinic acid.
Owner:RGT UNIV OF MINNESOTA
Anxioytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
InactiveUS20130065868A1Potent anxiolytic activityBiocideNervous disorderPharmaceutical drugPerylene derivatives
Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
Owner:UNIVERSITY OF OTTAWA
Pyrrole formamide derivative, and preparation method and application thereof
InactiveCN102786458AEnhanced inhibitory effectOrganic chemistryAntineoplastic agentsPharmaceutical medicineOncology
The present invention relates to compounds with a structure shown as a formula I or pharmaceutically acceptable salts thereof. R1, R2, R3, R4, R5 and R6 are defined as in the specification. The invention also provides a preparation method of the compounds with a structure shown as the formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compounds and pharmaceutically acceptable salts thereof, and application of betulinic acid analogues or solvates thereof as active ingredients to preparation of antineoplastic medicaments for treating lung cancer, prostate cancer, colon cancer, leukemia, breast cancer, liver cancer, gastric cancer, pancreatic cancer, human malignant glioma and brain tumor.
Owner:TIANJIN BOHAI VOCATIONAL TECHN COLLEGE
C-3 alkyl and alkenyl modified betulinic acid derivatives
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV:a compound of Formula Ia compound of Formula IIa compound of Formula IIIand a compound of Formula IVThese compounds are useful for the treatment of HIV and AIDS.
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Betulinic acid derivatives as Anti-hiv agents
InactiveUS20110152229A1Useful in treatmentOrganic active ingredientsAntiviralsAnti-HIV AgentMedicine
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL +1
Pharmaceutical Salts of 3-O-(3',3'-Dimethylsuccinyl) Betulinic Acid
Owner:MYREXIS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com